Momenta Pharmaceuticals, Inc. (MNTA) Latest to Take Advantage of Teva Pharmaceutical Industries Ltd (ADR) (TEVA)’s Patent Woes

Page 2 of 2

Remember that generic version of Lovenox mentioned a few paragraphs ago? Well, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) claims that later entrants infringed on its patents for manufacturing the drug. In a best-case scenario, those entrants would have to pay Momenta and Sandoz for lost sales from their competition, similar to Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Sun’s payments to Pfizer Inc. (NYSE:PFE) and Takeda. That is, of course, just speculation at this point.

The only worrisome news for Momenta is that Mylan Inc. (NASDAQ:MYL), being a bigger company, can absorb some competition. Momenta is much more desperate for immediate revenue. How does this end, er, begin? I’m afraid it will take several more months to determine exactly how things will play out. Still, Momenta investors can smile knowing that revenue will get here sooner rather than later.

The article Momenta Latest to Take Advantage of Teva’s Patent Woes originally appeared on Fool.com.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnologyThe Motley Fool recommends Momenta Pharmaceuticals (NASDAQ:MNTA). The Motley Fool owns shares of Momenta Pharmaceuticals.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2